---
firstreceived_date: September 12, 2014
is_fda_regulated: 'Yes'
reference: []
overall_contact_backup: {}
completion_date:
  attributes:
    type: Anticipated
  value: June 2016
responsible_party: {}
firstreceived_results_date: 
is_section_801: 'No'
detailed_description: {}
link: []
has_expanded_access: 'No'
id: NCT02241434
intervention:
- intervention_name: Stem Cell
  other_name: []
  description: 
  arm_group_label:
  - Stem Cell
  intervention_type: Biological
source: Neurogen Brain and Spine Institute
eligibility:
  gender: Both
  maximum_age: 25 Years
  sampling_method: 
  minimum_age: 3 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

                -  age group of 3-25 years

                -  Duchenne muscular dystrophy diagnosed on the basis of clinical presentation

              Exclusion Criteria:

                -  presence of respiratory distress

                -  presence of acute infections such as Human Immunodeficient Virus/Hepatitis B
                   Virus/Hepatitis C Virus

                -  malignancies

                -  acute medical conditions such as respiratory infection, fever, hemoglobin less than
                   8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%

                -  pregnancy or breastfeeding
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date:
  attributes:
    type: Anticipated
  value: January 2016
last_injected: '2015-09-26T11:26:17.909Z'
intervention_browse: {}
target_duration: 
number_of_arms: '1'
start_date: January 2009
why_stopped: 
id_info:
  org_study_id: NGBSI-13
  secondary_id: []
  nct_alias: []
  nct_id: NCT02241434
acronym: 
arm_group:
- description: 
  arm_group_label: Stem Cell
  arm_group_type: Experimental
sponsors:
  collaborator: []
  lead_sponsor:
    agency: Neurogen Brain and Spine Institute
    agency_class: Other
secondary_outcome:
- safety_issue: 'No'
  time_frame: 1 year
  description: 
  measure: Brooke and Vignos Scale
study_type: Interventional
biospec_retention: 
overall_status: Recruiting
primary_outcome:
- safety_issue: 'No'
  time_frame: 1 year
  description: 
  measure: Manual Muscle Testing
overall_official: []
phase: Phase 1
location_countries:
  country:
  - India
condition:
- Duchenne Muscular Dystrophy
clinical_results: {}
study_design: 'Endpoint Classification: Safety/Efficacy Study, Intervention Model:
  Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment'
keyword:
- Duchenne muscular dystrophy
- Autologous Bone marrow Mononuclear cell therapy
- Stem Cells
results_reference: []
oversight_info:
  has_dmc: 'Yes'
  authority:
  - 'India: Indian Council of Medical Research'
number_of_groups: 
location:
- status: Recruiting
  contact_backup: {}
  facility:
    name: Neurogen brain and spine institute
    address:
      city: Navi Mumbai
      state: Maharashtra
      zip: '400706'
      country: India
  investigator:
  - first_name: 
    last_name: Alok K Sharma, M.S, M.Ch
    middle_name: 
    affiliation: 
    degrees: 
    role: Principal Investigator
  contact:
    first_name: 
    last_name: Alok K Sharma, M.S, M.Ch
    middle_name: 
    phone_ext: 
    phone: 022-25283706
    degrees: 
    email: alok276@gmail.com
  geodata:
    latitude: 19.033
    formatted: Navi Mumbai, Maharashtra, India
    longitude: 73.03
    original: Navi Mumbai, Maharashtra
official_title: The Role of Autologous Bone Marrow Mononuclear Cell Therapy in Duchenne
  Muscular Dystrophy
verification_date: September 2014
required_header:
  url: https://clinicaltrials.gov/show/NCT02241434
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact:
  first_name: 
  last_name: Alok K Sharma, M.S, M.Ch
  middle_name: 
  phone_ext: 
  phone: 022-25283706
  degrees: 
  email: alok276@gmail.com
brief_title: Stem Cell Therapy in Duchenne Muscular Dystrophy
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophy, Duchenne
brief_summary:
  textblock: |-
    The purpose of this study was to study the effect of stem cell therapy in patients with
          Duchenne Muscular Dystrophy.
enrollment:
  attributes:
    type: Anticipated
  value: '500'
lastchanged_date: September 12, 2014
